跳到正文
原文
STAT 主站· Adam Feuerstein·· 4 天前精选AI 评分70

FDA 拒绝 Summit Therapeutics/Akeso 肺癌药物 ivonescimab 的上市申请

STAT+: FDA rejects lung cancer treatment ivonescimab from Summit Therapeutics

AI 导读

FDA 在致 Summit Therapeutics 和 Akeso 的信函中表示,ivoneskimab 虽能延缓部分肺癌患者的疾病进展,但未能延长患者生存期,因此不支持批准。该公司在美国主导 ivonescimab 的开发,此结果为该项目的监管 setback。

推荐理由

FDA 以无生存获益为由拒绝 ivonescimab 肺癌适应症的上市申请,反映了监管对总体生存的硬性门槛。

正文 · 原文

By Adam Feuerstein

Nov. 15, 2026

Adam Feuerstein, a senior writer and biotech columnist, is the author of Adam’s Biotech Scorecard, a subscriber-only newsletter about the crossroads of drug development, business, Wall Street, and biotechnology.

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast The Readout Loud and author of the newsletter Adam’s Biotech Scorecard. You can reach Adam on Signal at stataf.54.

The Food and Drug Administration rejected a treatment for a type of lung cancer developed by the U.S.-based biotech Summit Therapeutics and the Chinese drugmaker Akeso, Summit said on Sunday. 

In a letter sent to the companies, FDA regulators said the drug, called ivonescimab, could not be approved because it didn’t help patients live longer. While the drug was found to slow lung cancer worsening in patients, the absence of a survival benefit “does not support the positive benefit-risk profile in support of approval,” FDA reviewers concluded. 

The FDA’s rejection of ivonescimab is a regulatory setback for Summit, which oversees development of the drug outside of China, although one that was not entirely unforeseen. 

STAT+ Exclusive Story

Already have an account? Log in

STAT+

STAT+

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

View All Plans

To read the rest of this story subscribe to STAT+.

来源:STAT 主站 · statnews.com